# Expert Opinion on Investigational Drugs

**Type:** Journals  
**Canonical URL:** https://scholariq.org/journals/expert-opinion-on-investigational-drugs/

## Facts

| Field | Value |
| --- | --- |
| Citations | 136,231 |
| h-index | 132 |
| Homepage | http://informahealthcare.com/loi/eid |
| Open Access | false |
| ISSN-L | 1354-3784 |
| ISSNs | 1354-3784,1744-7658 |
| OpenAlex ID | https://openalex.org/S131064935 |
| Publisher | Taylor & Francis |
| Works | 5,116 |

## Journal papers

- [Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis](https://scholariq.org/papers/vandetanib-zd6474-an-orally-available-receptor-tyrosine-kinase-inhibitor-that/)
- [Neuropharmacology and potential efficacy of new treatments for tobacco dependence](https://scholariq.org/papers/neuropharmacology-and-potential-efficacy-of-new-treatments-for-tobacco/)
- [Update on treatment for idiopathic hypersomnia](https://scholariq.org/papers/update-on-treatment-for-idiopathic-hypersomnia/)
- [Emerging therapeutic strategies for minimal change disease and focal and segmental glomerulosclerosis](https://scholariq.org/papers/emerging-therapeutic-strategies-for-minimal-change-disease-and-focal-and/)
- [Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study](https://scholariq.org/papers/ciprofloxacin-dpi-in-non-cystic-fibrosis-bronchiectasis-a-phase-ii-randomized/)
- [IgA nephropathy: an overview of drug treatments in clinical trials](https://scholariq.org/papers/iga-nephropathy-an-overview-of-drug-treatments-in-clinical-trials/)
- [Duchenne muscular dystrophy: promising early-stage clinical trials to watch](https://scholariq.org/papers/duchenne-muscular-dystrophy-promising-early-stage-clinical-trials-to-watch/)
- [Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects](https://scholariq.org/papers/safety-and-pharmacokinetics-of-a-biosimilar-of-denosumab-kn012-phase-1-and/)
- [Tilsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma](https://scholariq.org/papers/tilsotolimod-an-investigational-synthetic-toll-like-receptor-9-tlr9-agonist-for/)

## Journal top topics

Showing 8 of 25.

- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [HIV/AIDS drug development and treatment](https://scholariq.org/topics/hiv-aids-drug-development-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Neurotransmitter Receptor Influence on Behavior](https://scholariq.org/topics/neurotransmitter-receptor-influence-on-behavior/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.